Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Collaborator: ViroPharma

Criteria

Inclusion Criteria:

• Men and women of non-childbearing potential.

• Hepatic impairment subjects: Child-Pugh class A, B, or C according to the C-P classification based on history, physical examination, and laboratory test results.

• Healthy volunteers: healthy as determined by the investigator.

Exclusion Criteria:

• History of alcoholism within 1 year.

• Hepatic impairment subjects: evidence of unstable clinically significant disease other than impaired hepatic function.

• Healthy volunteers: positive serologic findings for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibodies.